Adagene Inc. (ADAG) |
|
1.54 0.02 (1.32%)
|
03-24 11:01 |
|
Open: |
1.543 |
Pre. Close: |
1.52 |
|
High:
|
1.55 |
Low:
|
1.54 |
|
Volume:
|
1,160 |
Market Cap:
|
67(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 10:41:27 AM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.96 One year: 2.29 |
| Support: |
Support1: 1.24 Support2: 1.03 |
| Resistance: |
Resistance1: 1.68 Resistance2: 1.96 |
| Pivot: |
1.56  |
| Moving Average: |
MA(5): 1.54 MA(20): 1.6
MA(100): 1.45  MA(250): 1.88 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 46.8 %D(3): 49 |
| RSI: |
RSI(14): 41.5 |
| 52-week: |
High: 4.19 Low: 0.89 |
| Average Vol(K): |
3-Month: 26 (K) 10-Days: 16 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ADAG ] has closed above bottom band by 39.6%. Bollinger Bands are 6.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.65 - 1.67 |
1.67 - 1.68 |
|
Low:
|
1.5 - 1.52 |
1.52 - 1.54 |
|
Close:
|
1.51 - 1.55 |
1.55 - 1.57 |
|
Company Description |
|
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China. |
Headline News |
Sun, 05 Mar 2023
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board - Yahoo Finance
Fri, 16 Dec 2022
Adagene Announces Clinical Trial Collaboration to Evaluate Anti ... - GlobeNewswire
Mon, 10 Oct 2022
Immunic stock gains on $60M oversubscribed PIPE financing ... - Seeking Alpha
Tue, 30 Aug 2022
Adagene Reports Financial Results for the Six Months Ended June ... - GlobeNewswire
Thu, 30 Jun 2022
IMNM stock jumps after preclinical data on COVID-19 antibody ... - Seeking Alpha
Wed, 29 Jun 2022
Adagene Announces Authorization of Share Repurchase Program ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
43 (M) |
| Shares Float |
18 (M) |
|
% Held by Insiders
|
10.6 (%) |
|
% Held by Institutions
|
9.7 (%) |
|
Shares Short
|
8 (K) |
|
Shares Short P.Month
|
12 (K) |
Stock Financials |
|
EPS
|
-2.1 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.59 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-651 |
|
Return on Assets (ttm)
|
-26.2 |
|
Return on Equity (ttm)
|
-56 |
|
Qtrly Rev. Growth
|
188.6 |
|
Gross Profit (p.s.)
|
0.23 |
|
Sales Per Share
|
0.29 |
|
EBITDA (p.s.)
|
-1.89 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.73 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.58 |
|
Price to Sales
|
5.16 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
